Nico P E Vermeulen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9189494/publications.pdf

Version: 2024-02-01

281 papers	15,433 citations	29994 54 h-index	21474 114 g-index
288 all docs	288 docs citations	288 times ranked	14438 citing authors

#	Article	IF	Citations
1	Fish bioaccumulation and biomarkers in environmental risk assessment: a review. Environmental Toxicology and Pharmacology, 2003, 13, 57-149.	2.0	3,693
2	Biomarkers of free radical damage. Free Radical Biology and Medicine, 1999, 26, 202-226.	1.3	701
3	Paracetamol (Acetaminophen)-Induced Toxicity: Molecular and Biochemical Mechanisms, Analogues and Protective Approaches. Critical Reviews in Toxicology, 2001, 31, 55-138.	1.9	611
4	Enzyme-Catalyzed Activation of Anticancer Prodrugs. Pharmacological Reviews, 2004, 56, 53-102.	7.1	466
5	Managing the challenge of chemically reactive metabolites in drug development. Nature Reviews Drug Discovery, 2011, 10, 292-306.	21.5	382
6	Genetic Polymorphisms of HumanN-Acetyltransferase, Cytochrome P450, Glutathione-S-Transferase, and Epoxide Hydrolase Enzymes: Relevance to Xenobiotic Metabolism and Toxicity. Critical Reviews in Toxicology, 1999, 29, 59-124.	1.9	279
7	Oxygen and Xenobiotic Reductase Activities of Cytochrome P450. Critical Reviews in Toxicology, 1995, 25, 25-65.	1.9	217
8	Cytochrome P450 in Silico:Â An Integrative Modeling Approach. Journal of Medicinal Chemistry, 2005, 48, 2725-2755.	2.9	205
9	Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver. Biochemical Pharmacology, 1996, 51, 39-45.	2.0	198
10	Variability in nifedipine pharmacokinetics and dynamics: A new oxidation polymorphism in man. Biochemical Pharmacology, 1984, 33, 3721-3724.	2.0	176
11	A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chemical Research in Toxicology, 1992, 5, 211-219.	1.7	165
12	Biomonitoring of aquatic pollution with feral eel (Anguilla anguilla) II. Biomarkers: pollution-induced biochemical responses. Aquatic Toxicology, 1996, 36, 189-222.	1.9	156
13	The Role of Water Molecules in Computational Drug Design. Current Topics in Medicinal Chemistry, 2010, 10, 55-66.	1.0	155
14	Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products. Toxicology, 2007, 235, 83-91.	2.0	144
15	Catalytic Site Prediction and Virtual Screening of Cytochrome P450 2D6 Substrates by Consideration of Water and Rescoring in Automated Docking. Journal of Medicinal Chemistry, 2006, 49, 2417-2430.	2.9	138
16	Mercapturic Acids, Protein Adducts, and DNA Adducts as Biomarkers of Electrophilic Chemicals. Critical Reviews in Toxicology, 1992, 22, 271-306.	1.9	129
17	Binding Mode Prediction of Cytochrome P450 and Thymidine Kinase Proteinâ"Ligand Complexes by Consideration of Water and Rescoring in Automated Docking. Journal of Medicinal Chemistry, 2005, 48, 2308-2318.	2.9	121
18	Simultaneous determination of tyrosine, phenylalanine and deoxyguanosine oxidation products by liquid chromatographyâ€"tandem mass spectrometry as non-invasive biomarkers for oxidative damage. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 799, 245-254.	1.2	120

#	Article	IF	Citations
19	Homology Modeling of Rat and Human Cytochrome P450 2D (CYP2D) Isoforms and Computational Rationalization of Experimental Ligand-Binding Specificities. Journal of Medicinal Chemistry, 2003, 46, 74-86.	2.9	118
20	Cytotoxic and cytoprotective activities of curcumin. Biochemical Pharmacology, 1990, 39, 1869-1875.	2.0	117
21	Metabolism and Kinetics of Trichloroethylene in Relation to Toxicity and Carcinogenicity. Relevance of the Mercapturic Acid Pathway. Chemical Research in Toxicology, 1995, 8, 3-21.	1.7	117
22	Synthesis of Novel Se-Substituted Selenocysteine Derivatives as Potential Kidney Selective Prodrugs of Biologically Active Selenol Compounds:Â Evaluation of Kinetics of Î²-Elimination Reactions in Rat Renal Cytosol. Journal of Medicinal Chemistry, 1996, 39, 2040-2046.	2.9	108
23	Identification of Critical Residues in Novel Drug Metabolizing Mutants of Cytochrome P450 BM3 Using Random Mutagenesis. Journal of Medicinal Chemistry, 2007, 50, 455-461.	2.9	101
24	Monitoring of oxidative free radical damage in vivo: Analytical aspects. Chemico-Biological Interactions, 1992, 82, 243-293.	1.7	100
25	Evaluation of a Multi-parameter Biomarker Set for Oxidative Damage in Man: Increased Urinary Excretion of Lipid, Protein and DNA Oxidation Products after One Hour of Exercise. Free Radical Research, 2004, 38, 1269-1279.	1.5	100
26	A Three-Dimensional Protein Model for Human Cytochrome P450 2D6 Based on the Crystal Structures of P450 101, P450 102, and P450 108. Chemical Research in Toxicology, 1996, 9, 1079-1091.	1.7	97
27	Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3. Biochemical and Biophysical Research Communications, 2006, 346, 810-818.	1.0	93
28	Prediction of Ligand Binding Affinity and Orientation of Xenoestrogens to the Estrogen Receptor by Molecular Dynamics Simulations and the Linear Interaction Energy Method. Journal of Medicinal Chemistry, 2004, 47, 1018-1030.	2.9	92
29	Classification of Cytochrome P450 1A2 Inhibitors and Noninhibitors by Machine Learning Techniques. Drug Metabolism and Disposition, 2009, 37, 658-664.	1.7	91
30	Biomonitoring aquatic pollution with feral eel (Anguilla anguilla) I. Bioaccumulation: biota-sediment ratios of PCBs, OCPs, PCDDs and PCDFs. Aquatic Toxicology, 1996, 35, 21-46.	1.9	88
31	Diclofenac inhibits tumor necrosis factorâ€Î±â€induced nuclear factorâ€ÎºB activation causing synergistic hepatocyte apoptosis. Hepatology, 2011, 53, 2027-2041.	3.6	84
32	Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites. Chemico-Biological Interactions, 2008, 171, 96-107.	1.7	82
33	Molecular and biochemical mechanisms of chemically induced nephrotoxicity: a review. Chemical Research in Toxicology, 1990, 3, 171-194.	1.7	80
34	Virtual Screening and Prediction of Site of Metabolism for Cytochrome P450 1A2 Ligands. Journal of Chemical Information and Modeling, 2009, 49, 43-52.	2.5	78
35	The mechanism of prevention of paracetamol-induced hepatotoxicity by 3,5-dialkyl substitution. Biochemical Pharmacology, 1987, 36, 2065-2070.	2.0	77
36	Pharmacokinetics of Lignocaine and Bupivacaine in Surgical Patients Following Epidural Administration. Clinical Pharmacokinetics, 1987, 13, 191-203.	1.6	75

#	Article	IF	Citations
37	Formation of estrogenic metabolites of benzo[a]pyrene and chrysene by cytochrome P450 activity and their combined and supra-maximal estrogenic activity. Environmental Toxicology and Pharmacology, 2005, 19, 41-55.	2.0	75
38	The metabolic formation of N-acetyl-S-2-hydroxyethyl-L-cysteine from tetradeutero-1, 2-dibromoethane. Relative importance of oxidation and glutathione conjugation in vivo. Biochemical Pharmacology, 1981, 30, 2499-2502.	2.0	72
39	A Refined Substrate Model for Human Cytochrome P450 2D6. Chemical Research in Toxicology, 1997, 10, 41-48.	1.7	71
40	Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 513-527.	1.5	67
41	The role of lipid peroxidation in the nephrotoxicity of cisplatin. Biochemical Pharmacology, 1992, 44, 1193-1199.	2.0	66
42	Liquid Chromatography/Tandem Mass Spectrometry Detection of Covalent Binding of Acetaminophen to Human Serum Albumin. Drug Metabolism and Disposition, 2007, 35, 1408-1417.	1.7	66
43	Metabolic Regio- and Stereoselectivity of Cytochrome P450 2D6 towards 3,4-Methylenedioxy-N-alkylamphetamines:Â in Silico Predictions and Experimental Validation. Journal of Medicinal Chemistry, 2005, 48, 6117-6127.	2.9	64
44	Biomonitoring aquatic pollution with feral eel (Anguilla anguilla). III. Statistical analyses of relationships between contaminant exposure and biomarkers. Aquatic Toxicology, 1997, 39, 45-75.	1.9	63
45	Activation of the microsomal glutathione-s-transferase and reduction of the glutathione dependent protection against lipid peroxidation by acrolein. Biochemical Pharmacology, 1988, 37, 1933-1938.	2.0	61
46	BIOACCUMULATION, BIOTRANSFORMATION AND DNA BINDING OF PAHs IN FERAL EEL (ANGUILLA ANGUILLA) EXPOSED TO POLLUTED SEDIMENTS: A FIELD SURVEY. Environmental Toxicology and Chemistry, 1994, 13, 859.	2.2	61
47	Role of Human Glutathione S-Transferases in the Inactivation of Reactive Metabolites of Clozapine. Chemical Research in Toxicology, 2010, 23, 1467-1476.	1.7	60
48	A Comparative Linear Interaction Energy and MM/PBSA Study on SIRT1â€“Ligand Binding Free Energy Calculation. Journal of Chemical Information and Modeling, 2019, 59, 4018-4033.	2.5	60
49	Design, Synthesis, and Characterization of 7-Methoxy-4-(aminomethyl)coumarin as a Novel and Selective Cytochrome P450 2D6 Substrate Suitable for High-Throughput Screening. Chemical Research in Toxicology, 1999, 12, 555-559.	1.7	59
50	4-Hydroxy-2,3-trans-nonenal stimulates microsomal lipid peroxidation by reducing the glutathione-dependent protection. Archives of Biochemistry and Biophysics, 1987, 259, 449-456.	1.4	58
51	Nephrotoxicity of mercapturic acids of three structurally related 2,2-difluoroethylenes in the rat. Biochemical Pharmacology, 1988, 37, 4495-4504.	2.0	58
52	Effect of thiols on lipid peroxidation in rat liver microsomes. Chemico-Biological Interactions, 1989, 71, 201-212.	1.7	58
53	Are Automated Molecular Dynamics Simulations and Binding Free Energy Calculations Realistic Tools in Lead Optimization? An Evaluation of the Linear Interaction Energy (LIE) Method. Journal of Chemical Information and Modeling, 2006, 46, 1972-1983.	2.5	58
54	Legacy data sharing to improve drug safety assessment: the eTOX project. Nature Reviews Drug Discovery, 2017, 16, 811-812.	21.5	56

#	Article	IF	Citations
55	A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. Journal of Computer-Aided Molecular Design, 1993, 7, 281-289.	1.3	55
56	Evaluation of alkoxyresorufins as fluorescent substrates for cytochrome P450 BM3 and site-directed mutants. Analytical Biochemistry, 2005, 341, 148-155.	1.1	55
57	Toxicity of the cysteine-S-conjugates and mercapturic acids of four structurally related difluoroethylenes in isolated proximal tubular cells from rat kidney. Biochemical Pharmacology, 1989, 38, 3731-3741.	2.0	54
58	Selenoxidation by Flavin-Containing Monooxygenases as a Novel Pathway for Î²-Elimination of Selenocysteine Se-Conjugates. Chemical Research in Toxicology, 2001, 14, 127-134.	1.7	54
59	Comparative Study on the Bioactivation Mechanisms and Cytotoxicity of Te-Phenyl-l-tellurocysteine, Se-Phenyl-l-selenocysteine, and S-Phenyl-l-cysteine. Chemical Research in Toxicology, 2002, 15, 1610-1618.	1.7	54
60	Characterization of Human Cytochrome P450s Involved in the Bioactivation of Clozapine. Drug Metabolism and Disposition, 2013, 41, 651-658.	1.7	54
61	Prediction of Drug Metabolism: The Case of Cytochrome P450 2D6. Current Topics in Medicinal Chemistry, 2003, 3, 1227-1239.	1.0	53
62	Nephrotoxicity and hepatotoxicity of 1,1-dichloro-2,2-difluoroethylene in the rat. Biochemical Pharmacology, 1987, 36, 4229-4237.	2.0	51
63	A Single Active Site Mutation Inverts Stereoselectivity of 16â€Hydroxylation of Testosterone Catalyzed by Engineered Cytochrome P450â€‰BM3. ChemBioChem, 2012, 13, 520-523.	1.3	51
64	Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. Archives of Toxicology, 2016, 90, 2979-3003.	1.9	50
65	Mutagenicity and cytotoxicity of two regioisomeric mercapturic acids and cysteine S-conjugates of trichloroethylene. Archives of Toxicology, 1991, 65, 373-380.	1.9	49
66	A theoretical study on the metabolic activation of paracetamol by cytochrome P-450: indications for a uniform oxidation mechanism. Chemical Research in Toxicology, 1989, 2, 60-66.	1.7	46
67	Simultaneous determination of eight lipid peroxidation degradation products in urine of rats treated with carbon tetrachloride using gas chromatography with electron-capture detection. Biomedical Applications, 1997, 694, 277-287.	1.7	46
68	Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism. Biochemical Pharmacology, 2004, 68, 2263-2271.	2.0	46
69	The Use of Humanin VitroMetabolic Parameters to Explore the Risk Assessment of Hazardous Compounds: The Case of Ethylene Dibromide. Toxicology and Applied Pharmacology, 1997, 143, 56-69.	1.3	45
70	Molecular Modeling-Guided Site-Directed Mutagenesis of Cytochrome P450 2D6. Current Drug Metabolism, 2007, 8, 59-77.	0.7	45
71	Analysis of mercapturic acids as a tool in biotransformation, biomonitoring and toxicological studies. Trends in Pharmacological Sciences, 1989, 10, 177-181.	4.0	44
72	Role of residue 87 in substrate selectivity and regioselectivity of drug-metabolizing cytochrome P450 CYP102A1 M11. Journal of Biological Inorganic Chemistry, 2011, 16, 899-912.	1.1	44

#	Article	IF	Citations
73	The mechanism of interaction between cisplatin and selenite. Biochemical Pharmacology, 1991, 41, 1429-1437.	2.0	43
74	Biochemical markers in feral roach (Rutilus rutilus) in relation to the bioaccumulation of organic trace pollutants. Chemosphere, 1994, 29, 801-817.	4.2	43
75	Structural rationalization of novel drug metabolizing mutants of cytochrome P450 BM3. Proteins: Structure, Function and Bioinformatics, 2008, 71, 336-352.	1.5	39
76	Trimethoprim: Novel Reactive Intermediates and Bioactivation Pathways by Cytochrome P450s. Chemical Research in Toxicology, 2008, 21, 2181-2187.	1.7	39
77	Metabolism related toxicity of diclofenac in yeast as model system. Toxicology Letters, 2011, 200, 162-168.	0.4	39
78	Assessment of environmental quality and inland water pollution using biomarker responses in caged carp (Cyprinus carpio): Use of a bioactivation:detoxication ratio as a Biotransformation Index (BTI). Marine Environmental Research, 1998, 46, 315-319.	1.1	38
79	Role of the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6. Biochemical and Biophysical Research Communications, 2005, 338, 1065-1074.	1.0	38
80	Determination and identification of estrogenic compounds generated with biosynthetic enzymes using hyphenated screening assays, high resolution mass spectrometry and off-line NMR. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 667-674.	1.2	38
81	Efficient Screening of Cytochrome P450 BM3 Mutants for Their Metabolic Activity and Diversity toward a Wide Set of Drug-Like Molecules in Chemical Space. Drug Metabolism and Disposition, 2011, 39, 1568-1576.	1.7	38
82	Cytochrome P-450-mediated oxidation of substrates by electron-transfer; Role of oxygen radicals and of 1- and 2-electron oxidation of paracetamol. Chemico-Biological Interactions, 1988, 64, 267-280.	1.7	37
83	Selective induction of cytochrome P450 3A1 by dexamethasone in cultured rat hepatocytes. Biochemical Pharmacology, 2000, 60, 1509-1518.	2.0	37
84	Rapid On-line Profiling of Estrogen Receptor Binding Metabolites of Tamoxifen. Journal of Medicinal Chemistry, 2006, 49, 3287-3292.	2.9	37
85	Contribution of 4-hydroxy-2,3-trans-nonenal to the reduction of Î²-adrenoceptor function in the heart by oxidative stress. Life Sciences, 1989, 45, 71-76.	2.0	36
86	Structureâ€“activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. European Journal of Medicinal Chemistry, 2008, 43, 1621-1631.	2.6	36
87	Effect of UGT2B7*2 and CYP2C8*4 polymorphisms on diclofenac metabolism. Toxicology Letters, 2018, 284, 70-78.	0.4	36
88	Paracetamol, 3-monoalkyl- and 3,5-dialkyl derivatives. Biochemical Pharmacology, 1986, 35, 3693-3699.	2.0	35
89	Cytotoxicity of a series of mono- and di-substituted thiourea in freshly isolated rat hepatocytes: a preliminary structure-toxicity relationship study. Toxicology, 1998, 125, 117-129.	2.0	35
90	Induction of glutathione-S-transferase mRNA levels by chemopreventive selenocysteine Se-conjugates. Biochemical Pharmacology, 2002, 63, 1843-1849.	2.0	35

#	Article	IF	Citations
91	The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent. Biochemical Pharmacology, 2005, 70, 1253-1261.	2.0	35
92	Interactions between cytochromes P450, glutathione S-transferases and Ghanaian medicinal plants. Food and Chemical Toxicology, 2008, 46, 3598-3603.	1.8	35
93	Application of engineered cytochrome P450 mutants as biocatalysts for the synthesis of benzylic and aromatic metabolites of fenamic acid NSAIDs. Bioorganic and Medicinal Chemistry, 2014, 22, 5613-5620.	1.4	35
94	Inter-donor variability of phase I/phase II metabolism of three reference drugs in cryopreserved primary human hepatocytes in suspension and monolayer. Toxicology in Vitro, 2016, 33, 71-79.	1.1	35
95	Role of hepatic microsomal and purified cytochrome P-450 in one-electron reduction of two quinone imines and concomitant reduction of molecular oxygen. Biochemical Pharmacology, 1987, 36, 613-619.	2.0	33
96	Modeling the Active Sites of Cytochrome P450s and GlutathioneS-Transferases, two of the Most Important Biotransformation Enzymes. Drug Metabolism Reviews, 1997, 29, 747-799.	1.5	33
97	Combining substrate dynamics, binding statistics, and energy barriers to rationalize regioselective hydroxylation of octane and lauric acid by CYP102A1 and mutants. Protein Science, 2007, 16, 420-431.	3.1	33
98	Computational Prediction of Binding Affinity for CYP1A2-Ligand Complexes Using Empirical Free Energy Calculations. Drug Metabolism and Disposition, 2010, 38, 1347-1354.	1.7	33
99	Metabolism of l-cysteine S-conjugates and N-(trideuteroacetyl)-l-cysteineS-conjugates of four fluoroethylenes in the rat. Biochemical Pharmacology, 1991, 42, 31-38.	2.0	32
100	Evaluation of Urinary Biomarkers for Radical-Induced Liver Damage in Rats Treated with Carbon Tetrachloride. Toxicology and Applied Pharmacology, 1998, 148, 71-82.	1.3	32
101	Glutathioneâ€Sâ€transferase pi as a model protein for the characterisation of chemically reactive metabolites. Proteomics, 2008, 8, 301-315.	1.3	32
102	Mass Spectrometric Characterization of Protein Adducts of Multiple P450-Dependent Reactive Intermediates of Diclofenac to Human Glutathione-S-transferase P1-1. Chemical Research in Toxicology, 2012, 25, 2532-2541.	1.7	32
103	Mechanism of protection of ebselen against paracetamol-induced toxicity in rat hepatocytes. Biochemical Pharmacology, 1994, 48, 1631-1640.	2.0	31
104	Oxidative N-Dealkylation ofp-Cyclopropyl-N,N-dimethylaniline. A Substituent Effect on a Radical-Clock Reaction Rationalized by Ab Initio Calculations on Radical Cation Intermediates. Journal of Organic Chemistry, 1997, 62, 8227-8230.	1.7	31
105	Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 1999, 441, 73-83.	0.9	31
106	Activation of Microsomal Glutathione S-Transferase and Inhibition of Cytochrome P450 1A1 Activity as a Model System for Detecting Protein Alkylation by Thiourea-Containing Compounds in Rat Liver Microsomes. Chemical Research in Toxicology, 1999, 12, 396-402.	1.7	31
107	Differential involvement of mitochondrial dysfunction, cytochrome P450 activity, and active transport in the toxicity of structurally related NSAIDs. Toxicology in Vitro, 2012, 26, 197-205.	1.1	31
108	Evaluation of a novel high-throughput assay for cytochrome P450 2D6 using 7-methoxy-4-(aminomethyl)-coumarin. European Journal of Pharmaceutical Sciences, 2000, 12, 151-158.	1.9	30

#	Article	IF	Citations
109	Comparative cytotoxicity of N-substituted Nâ€²-(4-imidazole-ethyl)thiourea in precision-cut rat liver slices. Toxicology, 2004, 197, 80-90.	2.0	30
110	Regioâ€•and Stereoselective Hydroxylation of Optically Active Î±â€•Ionone Enantiomers by Engineered Cytochrome P450 BM3 Mutants. Advanced Synthesis and Catalysis, 2012, 354, 2172-2184.	2.1	30
111	Human NAD(P)H:quinone Oxidoreductase 1 (NQO1)-Mediated Inactivation of Reactive Quinoneimine Metabolites of Diclofenac and Mefenamic Acid. Chemical Research in Toxicology, 2014, 27, 576-586.	1.7	30
112	Principles of Pharmacology and Toxicology Also Govern Effects of Chemicals on the Endocrine System. Toxicological Sciences, 2015, 146, 11-15.	1.4	30
113	High-performance liquid chromatography-fluorescence assay of pyruvic acid to determine cysteine conjugate Î²-lyase activity: Application to S-1,2-dichlorovinyl-l-cysteine and S-2-benzothiazolyl-l-cysteine. Analytical Biochemistry, 1992, 206, 334-343.	1.1	29
114	Bioactivation of Chemopreventive Selenocysteine Se-Conjugates and Related Amino Acids by Amino Acid Oxidases Novel Route of Metabolism of Selenoamino Acids. Chemical Research in Toxicology, 2001, 14, 996-1005.	1.7	29
115	Cytochrome P450-Mediated Bioactivation of Mefenamic Acid to Quinoneimine Intermediates and Inactivation by Human Glutathione S-Transferases. Chemical Research in Toxicology, 2014, 27, 2071-2081.	1.7	29
116	Insights into regioselective metabolism of mefenamic acid by cytochrome <scp>P</scp>450 <scp>BM</scp>3 mutants through crystallography, docking, molecular dynamics, and free energy calculations. Proteins: Structure, Function and Bioinformatics, 2016, 84, 383-396.	1.5	29
117	One-electron reductive bioactivation of 2,3,5,6-tetramethylbenzoquinone by cytochrome P450. Biochemical Pharmacology, 1992, 43, 343-352.	2.0	28
118	Development of a Novel Cytochrome P450 Bioaffinity Detection System Coupled Online to Gradient Reversed-Phase High-Performance Liquid Chromatography. Journal of Biomolecular Screening, 2005, 10, 427-436.	2.6	28
119	Characterization of cytochrome P450 isoforms involved in sequential two-step bioactivation of diclofenac to reactive p-benzoquinone imines. Toxicology Letters, 2016, 253, 46-54.	0.4	28
120	Enantioselective Substrate Binding in a Monooxygenase Protein Model by Molecular Dynamics and Docking. Biophysical Journal, 2006, 91, 3206-3216.	0.2	26
121	Biotransformation of Endocrine Disrupting Compounds by Selected Phase I and Phase II Enzymes â€“ Formation of Estrogenic and Chemically Reactive Metabolites by Cytochromes P450 and Sulfotransferases. Current Medicinal Chemistry, 2014, 22, 500-527.	1.2	26
122	Polymorphism in the glutathione conjugation activity of human erythrocytes towards ethylene dibromide and 1,2-epoxy-3-(p-nitrophenoxy)-propane. Biochimica Et Biophysica Acta - General Subjects, 1995, 1243, 469-476.	1.1	25
123	Comparative cytotoxicity of 14 novel selenocysteine Se-conjugatesin rat renal proximal tubular cells. Toxicology and Applied Pharmacology, 1996, 141, 278-287.	1.3	25
124	Application of lipid peroxidation and protein oxidation biomarkers for oxidative damage in mammalian cells. A comparison with two fluorescent probes. Toxicology in Vitro, 2006, 20, 1005-1013.	1.1	25
125	Yeast as a Humanized Model Organism for Biotransformation-Related Toxicity. Current Drug Metabolism, 2012, 13, 1464-1475.	0.7	25
126	Biosynthesis of a steroid metabolite by an engineered Rhodococcus erythropolis strain expressing a mutant cytochrome P450 BM3 enzyme. Applied Microbiology and Biotechnology, 2015, 99, 4713-4721.	1.7	25

#	Article	IF	Citations
127	Activation of the microsomal glutathione S-transferase by metabolites of Î±-methyldopa. Archives of Biochemistry and Biophysics, 1991, 287, 48-52.	1.4	24
128	Characterization of enzyme activities and cofactors involved in bioactivation and bioinactivation of chemical carcinogens in the tester strains Escherichia coli K12 MX100 and Salmonella typhimurium LT2 TA100. Mutagenesis, 1997, 12, 245-254.	1.0	24
129	Urinary excretion of biomarkers for radical-induced damage in rats treated with NDMA or diquat and the effects of calcium carbimide co-administration. Chemico-Biological Interactions, 1999, 117, 151-172.	1.7	24
130	Characterization of human cytochrome P450 mediated bioactivation of amodiaquine and its major metabolite Nâ€desethylamodiaquine. British Journal of Clinical Pharmacology, 2017, 83, 572-583.	1.1	24
131	Ab initio calculations on iron-porphyrin model systems for intermediates in the oxidative cycle of cytochrome P450s. Journal of Computer-Aided Molecular Design, 1998, 12, 183-193.	1.3	23
132	Effect of Human Glutathione S-Transferases on Glutathione-Dependent Inactivation of Cytochrome P450-Dependent Reactive Intermediates of Diclofenac. Chemical Research in Toxicology, 2013, 26, 1632-1641.	1.7	23
133	Linear Interaction Energy Based Prediction of Cytochrome P450 1A2 Binding Affinities with Reliability Estimation. PLoS ONE, 2015, 10, e0142232.	1.1	23
134	Paracetamol, 3-monoalkyl- and 3,5-dialkyl-substituted derivatives. Biochemical Pharmacology, 1988, 37, 3473-3476.	2.0	22
135	A physiologically-based pharmacokinetic(PB-PK) model for ethylene dibromide: relevance of extrahepatic metabolism. Food and Chemical Toxicology, 2000, 38, 707-716.	1.8	22
136	Application of CYP102A1M11H as a Tool for the Generation of Protein Adducts of Reactive Drug Metabolites. Chemical Research in Toxicology, 2011, 24, 1263-1274.	1.7	22
137	Simulation of interindividual differences in inactivation of reactive para -benzoquinone imine metabolites of diclofenac by glutathione S -transferases in human liver cytosol. Toxicology Letters, 2016, 255, 52-62.	0.4	22
138	Chemistry and Biological Activity of Novel Selenium-Containing Compounds. Advances in Experimental Medicine and Biology, 2001, 500, 105-112.	0.8	22
139	Genetic deficiency of human class mu glutathione S-transferase isoenzymes in relation to the urinary excretion of the mercapturic acids of Z- and E-1,3-dichloropropene. Archives of Toxicology, 1991, 65, 95-99.	1.9	21
140	In vitro inhibition of rat and human glutathione S-transferase isoenzymes by disulfiram and diethyldithiocarbamate. Biochemical Pharmacology, 1996, 52, 197-204.	2.0	21
141	Escherichia coli MTC, a NADPH cytochrome P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450: Comparison of three types of expression systems. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 1999, 439, 287-300.	0.9	21
142	Development and validation of a fluorescence HPLC-based screening assay for inhibition of human estrogen sulfotransferase. Analytical Biochemistry, 2006, 357, 85-92.	1.1	21
143	Online Biochemical Detection of Glutathione-S-Transferase P1-Specific Inhibitors in Complex Mixtures. Journal of Biomolecular Screening, 2007, 12, 396-405.	2.6	21
144	Subunits Rip1p and Cox9p of the respiratory chain contribute to diclofenac-induced mitochondrial dysfunction. Microbiology (United Kingdom), 2011, 157, 685-694.	0.7	21

#	Article	IF	Citations
145	Towards Automated Binding Affinity Prediction Using an Iterative Linear Interaction Energy Approach. International Journal of Molecular Sciences, 2014, 15, 798-816.	1.8	21
146	Effect of human glutathione S-transferase hGSTP1-1 polymorphism on the detoxification of reactive metabolites of clozapine, diclofenac and acetaminophen. Toxicology Letters, 2014, 224, 272-281.	0.4	21
147	Linking cytochrome P450 enzymes from Mycobacterium tuberculosis to their cognate ferredoxin partners. Applied Microbiology and Biotechnology, 2018, 102, 9231-9242.	1.7	21
148	Determination of cisplatin and related platinum complexes in plasma ultrafiltrate and urine by high-performance liquid chromatography with on-line radioactivity detection. Biomedical Applications, 1989, 491, 163-174.	1.7	20
149	3,5-Disubstituted analogues of paracetamol. Synthesis, analgesic activity and cytotoxicity. Chemico-Biological Interactions, 1995, 98, 237-250.	1.7	20
150	Tissue distribution of cytosolic Î²-elimination reactions of selenocysteine Se-conjugates in rat and human. Chemico-Biological Interactions, 2002, 140, 243-264.	1.7	20
151	Development of Three Parallel Cytochrome P450 Enzyme Affinity Detection Systems Coupled On-line to Gradient High-Performance Liquid Chromatography. Drug Metabolism and Disposition, 2007, 35, 640-648.	1.7	20
152	Metabolic Profiling of Endocrine-Disrupting Compounds by On-Line Cytochrome P450 Bioreaction Coupled to On-Line Receptor Affinity Screening. Chemical Research in Toxicology, 2007, 20, 1825-1832.	1.7	20
153	Free energies of binding of R- and S-propranolol to wild-type and F483A mutant cytochrome P450 2D6 from molecular dynamics simulations. European Biophysics Journal, 2007, 36, 589-599.	1.2	20
154	Interactions of organophosphates with keratins in the cornified epithelium of human skin. Chemico-Biological Interactions, 2012, 197, 93-102.	1.7	20
155	Different Reactive Metabolites of Nevirapine Require Distinct Glutathione S-Transferase Isoforms for Bioinactivation. Chemical Research in Toxicology, 2016, 29, 2136-2144.	1.7	20
156	Comprehensive and Automated Linear Interaction Energy Based Binding-Affinity Prediction for Multifarious Cytochrome P450 Aromatase Inhibitors. Journal of Chemical Information and Modeling, 2017, 57, 2294-2308.	2.5	20
157	Simultaneous determination of glutathione, glutathione disulphide, paracetamol and its sulphur containing metabolites using HPLC and electrochemical detection with on-line generated bromine. Journal of Pharmaceutical and Biomedical Analysis, 1988, 6, 329-336.	1.4	19
158	Purification of Glutamine Transaminase K/Cysteine Conjugate Î²-Lyase from Rat Renal Cytosol Based on Hydrophobic Interaction HPLC and Gel Permeation FPLC. Protein Expression and Purification, 1993, 4, 552-562.	0.6	19
159	Bioactivation of Dibrominated Biphenyls by Cytochrome P450 Activity to Metabolites with Estrogenic Activity and Estrogen Sulfotransferase Inhibition Capacity. Chemical Research in Toxicology, 2005, 18, 1691-1700.	1.7	19
160	Binding of bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine to wild-type and F120A mutant cytochrome P450 2D6 studied by resonance Raman spectroscopy. Biochemical and Biophysical Research Communications, 2006, 343, 772-779.	1.0	19
161	Automated detection of covalent adducts to human serum albumin by immunoaffinity chromatography, on-line solution phase digestion and liquid chromatographyâ€“mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 859, 147-156.	1.2	19
162	Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants. Toxicology Letters, 2015, 232, 182-192.	0.4	19

#	Article	IF	Citations
163	Binding free energy predictions of farnesoid X receptor (FXR) agonists using a linear interaction energy (LIE) approach with reliability estimation: application to the D3R Grand Challenge 2. Journal of Computer-Aided Molecular Design, 2018, 32, 239-249.	1.3	19
164	Human multidrug resistance protein 4 (MRP4) is a cellular efflux transporter for paracetamol glutathione and cysteine conjugates. Archives of Toxicology, 2020, 94, 3027-3032.	1.9	19
165	Bioactivation ofS-(2,2-Dihalo-1,1-difluoroethyl)-l- cysteines andS-(Trihalovinyl)-l-cysteines by Cysteine S-Conjugate Î²-Lyase:Â Indications for Formation of both Thionoacylating Species and Thiiranes as Reactive Intermediates. Chemical Research in Toxicology, 1996, 9, 1092-1102.	1.7	18
166	Novel piperidine derivatives: inhibitory properties towards cytochrome P450 isoforms, and cytoprotective and cytotoxic characteristics. Environmental Toxicology and Pharmacology, 1996, 1, 81-88.	2.0	18
167	MX100, a new Escherichia coli tester strain for use in genotoxicity studies. Mutagenesis, 1996, 11, 327-333.	1.0	18
168	Reversed-phase liquid chromatography coupled on-line to estrogen receptor bioaffinity detection based on fluorescence polarization. Analytical and Bioanalytical Chemistry, 2008, 390, 1987-1998.	1.9	18
169	Comparison of murine and human estrogen sulfotransferase inhibition in vitro and in silicoâ€"Implications for differences in activity, subunit dimerization and substrate inhibition. Molecular and Cellular Endocrinology, 2010, 317, 127-140.	1.6	18
170	Malleability and Versatility of Cytochrome P450 Active Sites Studied by Molecular Simulations. Current Drug Metabolism, 2012, 13, 190-196.	0.7	18
171	Metabolite Predictions for Para-Substituted Anisoles Based on ab Initio Complete Active Space Self-Consistent Field Calculations. Chemical Research in Toxicology, 1995, 8, 437-443.	1.7	17
172	Structure-activity relationships for chemical and glutathione S-transferase-catalysed glutathione conjugation reactions of a series of 2-substituted 1-chloro-4-nitrobenzenes. Biochemical Journal, 1996, 320, 531-540.	1.7	17
173	Strategies to Characterize the Mechanisms of Action and the Active Sites of GlutathioneS-Transferases: A Review. Drug Metabolism Reviews, 1998, 30, 569-643.	1.5	17
174	Î²-Lyase-Dependent Attenuation of Cisplatin-Mediated Toxicity by SelenocysteineSe-Conjugates in Renal Tubular Cell Lines. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 884-892.	1.3	17
175	Integrative Modeling Strategies for Predicting Drug Toxicities at the eTOX Project. Molecular Informatics, 2015, 34, 477-484.	1.4	17
176	Conventional and Novel Approaches in Generating and Characterization of Reactive Intermediates from Drugs/Drug Candidates. Current Drug Metabolism, 2011, 12, 383-394.	0.7	17
177	The influence of ebselen on the toxicity of cisplatin in LLC-PK1 cells. Biochemical Pharmacology, 1992, 44, 382-387.	2.0	16
178	Mechanism of protection of lobenzarit against paracetamol-induced toxicity in rat hepatocytes. European Journal of Pharmacology - Environmental Toxicology and Pharmacology Section, 1995, 293, 301-308.	0.8	16
179	A Homology Model for Rat Mu Class Glutathione S-Transferase 4-4. Chemical Research in Toxicology, 1996, 9, 28-40.	1.7	16
180	Active-site structure, binding and redox activity of the hemeâ€"thiolate enzyme CYP2D6 immobilized on coated Ag electrodes: a surface-enhanced resonance Raman scattering study. Journal of Biological Inorganic Chemistry, 2008, 13, 85-96.	1.1	16

#	Article	IF	Citations
181	Inter-individual Variability in Activity of the Major Drug Metabolizing Enzymes in Liver Homogenates of 20 Individuals. Current Drug Metabolism, 2018, 19, 370-381.	0.7	16
182	Paracetamol, 3-monoalkyl- and 3,5-dialkyl derivatives: Comparison of their hepatotoxicity in mice. Toxicology and Applied Pharmacology, 1987, 89, 183-189.	1.3	15
183	Determination of two mercapturic acid metabolites of 1,3-dichloropropene in human urine with gas chromatography and sulphur-selective detection. Biomedical Applications, 1989, 496, 463-471.	1.7	15
184	Cytochromes P450 and drug resistance. Cytotechnology, 1993, 12, 357-366.	0.7	15
185	3-Chloro-2-hydroxypropylmercapturic acid and Î±-chlorohydrin as biomarkers of occupational exposure to epichlorohydrin. Environmental Toxicology and Pharmacology, 1997, 3, 175-185.	2.0	15
186	The use of in vitro metabolic parameters and physiologically based pharmacokinetic (PBPK) modeling to explore the risk assessment of trichloroethylene. Environmental Toxicology and Pharmacology, 2002, 11, 259-271.	2.0	15
187	Development and validation of a microsomal online cytochrome P450 bioreactor coupled to solid-phase extraction and reversed-phase liquid chromatography. Journal of Chromatography A, 2005, 1075, 205-212.	1.8	15
188	Topological role of cytochrome P450 2D6 active site residues. Archives of Biochemistry and Biophysics, 2006, 447, 53-58.	1.4	15
189	An on-line post-column detection system for the detection of reactive-oxygen-species-producing compounds and antioxidants in mixtures. Analytical and Bioanalytical Chemistry, 2007, 388, 871-879.	1.9	15
190	Application of a Fluorescence-Based Continuous-Flow Bioassay to Screen for Diversity of Cytochrome P450 BM3 Mutant Libraries. Journal of Biomolecular Screening, 2011, 16, 239-250.	2.6	15
191	Characterization of kinetics of human cytochrome <scp>P</scp>450s involved in bioactivation of flucloxacillin: inhibition of <scp>CYP</scp>3<scp>A</scp>â€catalysed hydroxylation by sulfaphenazole. British Journal of Pharmacology, 2019, 176, 466-477.	2.7	15
192	Examination of the structure-toxicity relationships of l-cysteine-S-conjugates of halogenated alkenes and their corresponding mercapturic acids in rat renal tissue slices. Toxicology, 1993, 79, 67-79.	2.0	14
193	Identification and quantitative determination of 3-chloro-2-hydroxypropylmercapturic acid and Î±-chlorohydrin in urine of rats treated with epichlorohydrin. Biomedical Applications, 1996, 685, 241-250.	1.7	14
194	Heterologous Expression of Xenobiotic Mammalian-Metabolizing Enzymes in Mutagenicity Tester Bacteria: An Update and Practical Considerations. Critical Reviews in Toxicology, 2000, 30, 287-306.	1.9	14
195	Cytochrome P450 bio-affinity detection coupled to gradient HPLC: On-line screening of affinities to cytochrome P4501A2 and 2D6. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 858, 49-58.	1.2	14
196	Role of Residue 87 in the Activity and Regioselectivity of Clozapine Metabolism by Drug-Metabolizing CYP102A1 M11H: Application for Structural Characterization of Clozapine GSH Conjugates. Drug Metabolism and Disposition, 2011, 39, 2411-2420.	1.7	14
197	Involvement of the Pleiotropic Drug Resistance Response, Protein Kinase C Signaling, and Altered Zinc Homeostasis in Resistance of Saccharomyces cerevisiae to Diclofenac. Applied and Environmental Microbiology, 2011, 77, 5973-5980.	1.4	14
198	Free Energy Calculations Give Insight into the Stereoselective Hydroxylation of Î±-Ionones by Engineered Cytochrome P450 BM3 Mutants. Journal of Chemical Information and Modeling, 2012, 52, 2139-2148.	2.5	14

#	Article	IF	Citations
199	One-electron oxidation of diclofenac by human cytochrome P450s as a potential bioactivation mechanism for formation of 2â€²-(glutathion-S-yl)-deschloro-diclofenac. Chemico-Biological Interactions, 2014, 207, 32-40.	1.7	14
200	Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations. Chemical Research in Toxicology, 2018, 31, 116-126.	1.7	14
201	A combined computational and experimental study on selective flucloxacillin hydroxylation by cytochrome P450 BM3 variants. Journal of Inorganic Biochemistry, 2018, 184, 115-122.	1.5	14
202	Application of cytochrome P450 BM3 mutants as biocatalysts for the profiling of estrogen receptor binding metabolites of the mycotoxin zearalenone. Xenobiotica, 2011, 41, 59-70.	0.5	13
203	Combination of biotransformation by P450 BM3 mutants with on-line post-column bioaffinity and mass spectrometric profiling as a novel strategy to diversify and characterize p38Î± kinase inhibitors. MedChemComm, 2013, 4, 371-377.	3.5	13
204	Simultaneous determination of blood concentrations of methohexital and its hydroxy metabolite by gas chromatography and identification of 4â€²-hydroxymethohexital by combined gasâ€"liquid chromatographyâ€"mass spectrometry. Biomedical Applications, 1981, 226, 403-412.	1.7	12
205	Inter-individual variability in the oxidation of 1,2-dibromoethane: use of heterologously expressed human cytochrome P450 and human liver microsomes. Chemico-Biological Interactions, 1996, 101, 175-192.	1.7	12
206	Molecular mechanisms of toxic effects of fotemustine in rat hepatocytes and subcellular rat liver fractions. Carcinogenesis, 1996, 17, 715-724.	1.3	12
207	Urinary Metabolite Profile of Phenyl and o-Cresyl Glycidyl Ether in Rats:â€‰ Identification of a Novel Pathway Leading to N-Acetylserine O-Conjugates. Chemical Research in Toxicology, 1998, 11, 111-118.	1.7	12
208	Binding of 7-methoxy-4-(aminomethyl)-coumarin to wild-type and W128F mutant cytochrome P450 2D6 studied by time-resolved fluorescence spectroscopy. Biochemical Journal, 2006, 393, 635-643.	1.7	12
209	The Role of Protein Plasticity in Computational Rationalization Studies on Regioselectivity in Testosterone Hydroxylation by Cytochrome P450 BM3 Mutants. Current Drug Metabolism, 2012, 13, 155-166.	0.7	12
210	Characterization of Human Cytochrome P450s Involved in the Bioactivation of Tri-ortho-cresyl Phosphate (ToCP). Chemical Research in Toxicology, 2015, 28, 711-721.	1.7	12
211	Improving the iterative Linear Interaction Energy approach using automated recognition of configurational transitions. Journal of Molecular Modeling, 2016, 22, 31.	0.8	12
212	Human glutathione S-transferases- and NAD(P)H:quinone oxidoreductase 1-catalyzed inactivation of reactive quinoneimines of amodiaquine and N-desethylamodiaquine: Possible implications for susceptibility to amodiaquine-induced liver toxicity. Toxicology Letters, 2017, 275, 83-91.	0.4	12
213	A Predictive Substrate Model for Rat Glutathione S-Transferase 4-4. Chemical Research in Toxicology, 1995, 8, 649-658.	1.7	11
214	Endocrine disrupting chemicalsâ€"Linking internal exposure to vitellogenin levels and ovotestis in Abramis brama from Dutch surface waters. Environmental Toxicology and Pharmacology, 2010, 30, 209-223.	2.0	11
215	Selective whole-cell biosynthesis of the designer drug metabolites 15- or 16-betahydroxynorethisterone by engineered Cytochrome P450 BM3 mutants. Journal of Molecular Catalysis B: Enzymatic, 2015, 121, 64-74.	1.8	11
216	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity: how to evaluate the risk of the S-EDCs?. Archives of Toxicology, 2020, 94, 2549-2557.	1.9	11

#	Article	IF	Citations
217	Assay of pemoline in human plasma, saliva and urine by capillary gas chromatography with nitrogen-selective detection. Journal of Chromatography A, 1978, 157, 133-140.	1.8	10
218	Toxicity of fotemustine in rat hepatocytes and mechanism-based protection against it. Chemico-Biological Interactions, 1998, 110, 139-158.	1.7	10
219	Selection of effective antisense oligodeoxynucleotides with a green fluorescent protein-based assay. FEBS Journal, 2002, 269, 2574-2583.	0.2	10
220	In Vitro Biotransformation of 3,4-Dihydro-6-hydroxy-2,2-dimethyl-7-methoxy-1(2H)-Benzopyran (CR-6), a Potent Lipid Peroxidation Inhibitor and Nitric Oxide Scavenger, in Rat Liver Microsomes. Chemical Research in Toxicology, 2004, 17, 904-913.	1.7	10
221	A novel microplate reader-based high-throughput assay for estrogen receptor binding. International Journal of Environmental Analytical Chemistry, 2005, 85, 149-161.	1.8	10
222	Altered spin state equilibrium in the T309V mutant of cytochrome P450 2D6: a spectroscopic and computational study. Journal of Biological Inorganic Chemistry, 2007, 12, 645-654.	1.1	10
223	Urinary lipid and protein oxidation products upon halothane, isoflurane, or sevoflurane anesthesia in humans: potential biomarkers for a subclinical nephrotoxicity. Biomarkers, 2013, 18, 73-81.	0.9	10
224	Mass spectrometric identification of isocyanate-induced modifications of keratins in human skin. Chemico-Biological Interactions, 2015, 237, 141-150.	1.7	10
225	Hexobarbital-1â€²,2â€²-epoxide: A possible intermediate in the metabolism of hexobarbital. Biochemical Pharmacology, 1978, 27, 135-138.	2.0	9
226	Reductase and oxidase activity of rat liver cytochrome P450 with 2,3,5,6-tetramethylbenzoquinone as substrate. Chemico-Biological Interactions, 1992, 83, 249-269.	1.7	9
227	4-Substituted 1-Chloro-2-nitrobenzenes:Â Structureâ^'Activity Relationships and Extension of the Substrate Model of Rat GlutathioneS-Transferase 4-4. Chemical Research in Toxicology, 1997, 10, 439-449.	1.7	9
228	Surface-Enhanced Resonance Raman Scattering of Cytochrome P450-2D6 on Coated Silver Hydrosols. Langmuir, 2007, 23, 1860-1866.	1.6	9
229	Structureâ^'Activity Relationships for the Glutathione Conjugation of 2-Substituted 1-Chloro-4-nitrobenzenes by Rat Glutathione S-Transferase 4-4. Chemical Research in Toxicology, 1996, 9, 527-534.	1.7	8
230	Identification of CYP1A2 ligands by structure-based and ligand-based virtual screening. MedChemComm, 2011, 2, 853.	3.5	8
231	Direct comparison of UDP-glucuronosyltransferase and cytochrome P450 activities in human liver microsomes, plated and suspended primary human hepatocytes from five liver donors. European Journal of Pharmaceutical Sciences, 2017, 109, 96-110.	1.9	8
232	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2020, 83, 485-494.	1.1	8
233	Response to â€œThe Path Forward on Endocrine Disruptors Requires Focusâ€• Toxicological Sciences, 2016, 149, 273-4.	1.4	8
234	The Use of Macroporous Microcarriers for the Large-Scale Growth of V79 Cells Genetically Designed to Express Single Human Cytochrome P450 Isoenzymes and for the Characterization of the Expressed Cytochrome P450. Protein Expression and Purification, 1996, 8, 439-446.	0.6	7

#	Article	IF	Citations
235	Cytochrome P450 catalyzed metabolism of 1,2-dibromoethane in liver microsomes of differentially induced rats. Chemico-Biological Interactions, 1996, 99, 41-53.	1.7	7
236	A Flow-Through Fluorescence Polarization Detection System for Measuring GPCR-Mediated Modulation of cAMP Production. Journal of Biomolecular Screening, 2007, 12, 1074-1083.	2.6	7
237	Application of a Continuous-Flow Bioassay to Investigate the Organic Solvent Tolerability of Cytochrome P450 BM3 Mutants. Journal of Biomolecular Screening, 2015, 20, 1246-1255.	2.6	7
238	eTOX ALLIES: an automated pipeLine for linear interaction energy-based simulations. Journal of Cheminformatics, 2017, 9, 58.	2.8	7
239	Engineering a self-sufficient Mycobacterium tuberculosis CYP130 by gene fusion with the reductase-domain of CYP102A1 from Bacillus megaterium. Journal of Inorganic Biochemistry, 2018, 180, 47-53.	1.5	7
240	Glutathione S-Transferase P1 Protects Against Amodiaquine Quinoneimines-Induced Cytotoxicity but Does Not Prevent Activation of Endoplasmic Reticulum Stress in HepG2 Cells. Frontiers in Pharmacology, 2018, 9, 388.	1.6	7
241	The EU chemicals strategy for sustainability: in support of the BfR position. Archives of Toxicology, 2021, 95, 3133-3136.	1.9	7
242	Bioaccumulation of Organic Micropollutants in Different Aquatic Organisms: Sublethal Toxic Effects on Fish. , 0, , 166-166-15.		7
243	The cytotoxicity of mitomycin C and Adriamycin in genetically engineered V79 cell lines and freshly isolated rat hepatocytes. Chemico-Biological Interactions, 1995, 97, 149-168.	1.7	6
244	Cytotoxicity of paracetamol and 3,5-dihalogenated analogues: Role of cytochrome P-450 and formation of GSH conjugates and protein adducts. Toxicology in Vitro, 1997, 11, 9-19.	1.1	6
245	Screening the Oxidative Potential of Several Mono- and Di-Halogenated Biphenyls and Biphenyl Ethers in Rat Hepatocytes. Combinatorial Chemistry and High Throughput Screening, 2006, 9, 449-454.	0.6	6
246	Bioactivation of N-substituted Nâ€²-(4-imidazole-ethyl)thioureas by human FMO1 and FMO3. Xenobiotica, 2006, 36, 645-657.	0.5	5
247	In Vitro Bioactivation of 3-(N-Phenylamino)propane-1,2-diol by Human and Rat Liver Microsomes and Recombinant P450 Enzymes. Implications for Toxic Oil Syndrome. Chemical Research in Toxicology, 2007, 20, 1218-1224.	1.7	5
248	Molecular dynamics simulations and free energy calculations on the enzyme 4â€hydroxyphenylpyruvate dioxygenase. Journal of Computational Chemistry, 2011, 32, 2160-2169.	1.5	5
249	Reconstitution of the interplay between cytochrome P450 and human glutathione S-transferases in clozapine metabolism in yeast. Toxicology Letters, 2013, 222, 247-256.	0.4	5
250	Application of a cocktail approach to screen cytochrome P450 BM3 libraries for metabolic activity and diversity. Analytical and Bioanalytical Chemistry, 2016, 408, 1425-1443.	1.9	5
251	Drug toxicity profiling of a Saccharomyces cerevisiae deubiquitinase deletion panel shows that acetaminophen mimics tyrosine. Toxicology in Vitro, 2018, 47, 259-268.	1.1	5
252	Acetaminophen reduces the protein levels of high affinity amino acid permeases and causes tryptophan depletion. Amino Acids, 2018, 50, 1377-1390.	1.2	5

#	Article	IF	Citations
253	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Chemico-Biological Interactions, 2020, 326, 109099.	1.7	5
254	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Toxicology in Vitro, 2020, 67, 104861.	1.1	5
255	Selection of antisense oligodeoxynucleotides against glutathione S-transferase Mu. Rna, 2002, 8, 1572-83.	1.6	5
256	Correlation between the in vivo Metabolism of Hexobarbital and Antipyrine in Rats with a Portacaval Shunt. Pharmacology, 1984, 29, 99-109.	0.9	4
257	Determination of 75Se-labelled selenite and metabolites in plasma and urine by high-performance liquid chromatography with on-line radioactivity detection. Biomedical Applications, 1989, 496, 111-120.	1.7	4
258	Generic method for the absolute quantification of glutathione S-conjugates: Application to the conjugates of acetaminophen, clozapine and diclofenac. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1046, 185-194.	1.2	4
259	The effect of acetaminophen on ubiquitin homeostasis in Saccharomyces cerevisiae. PLoS ONE, 2017, 12, e0173573.	1.1	4
260	Correlation of apparent intrinsic clearances of simultaneously administered S (+) and d3R (â^') hexobarbital in the rat. Biochemical Pharmacology, 1987, 36, 1321-1323.	2.0	3
261	Bioassays for the detection of chemicals that can form bioactivationâ€dependent reactive free radicals. Environmental Toxicology and Chemistry, 1999, 18, 1236-1243.	2.2	3
262	[19] Enzymatic pathways of Î² elimination of chemopreventive selenocysteine Se conjugates. Methods in Enzymology, 2002, 348, 191-200.	0.4	3
263	High-performance liquid chromatography-based assay for glutathione transferase theta 2 activity: Application to characterize interindividual variability in human liver fractions. Journal of Pharmaceutical and Biomedical Analysis, 2018, 156, 181-188.	1.4	3
264	Glossary and tutorial of xenobiotic metabolism terms used during small molecule drug discovery and development (IUPAC Technical Report). Pure and Applied Chemistry, 2021, 93, 273-403.	0.9	3
265	Reduction of Antitumour Mitosenes in Non-Aqueous and Aqueous Environment. An Electron Spin Resonance and Cyclic Voltammetry Study. Free Radical Research, 1995, 22, 109-121.	1.5	2
266	Mini-dialysis tubes as tools to prepare drug-protein adducts of P450-dependent reactive drug metabolites. Journal of Pharmaceutical and Biomedical Analysis, 2015, 103, 17-25.	1.4	2
267	The Role and Application of In Silico Docking in Chemical Genomics Research. Methods in Molecular Biology, 2005, 310, 63-91.	0.4	2
268	The influence of pretreatment on the urinary metabolite profile of pseudoracemic hexobarbital. Biochemical Pharmacology, 1986, 35, 3166-3169.	2.0	1
269	Influence of the Rate of Hepatic Portal Vein Infusion on Hexobarbital Pharmacokinetics in the Rat. Pharmacology, 1988, 36, 210-216.	0.9	1
270	Protective effects of lobenzarit against allyl alcohol-induced hepatotoxicity in mice and rats. Environmental Toxicology and Pharmacology, 1997, 3, 129-135.	2.0	1

#	Article	IF	Citations
271	Cytochrome P450 in Silico: An Integrative Modeling Approach. ChemInform, 2005, 36, no.	0.1	1
272	European Modular Education and Training Programme in Safety Sciences for Medicines (SafeSciMET). Toxicology Letters, 2009, 189, S266-S267.	0.4	1
273	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Toxicology Letters, 2020, 331, 259-264.	0.4	1
274	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Environmental Toxicology and Pharmacology, 2020, 78, 103396.	2.0	1
275	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Food and Chemical Toxicology, 2020, 142, 111349.	1.8	1
276	Cytochrome P450 Protein Modeling and Ligand Docking. , 2019, , 435-470.		1
277	Active site mapping of various cytochromes P450 isozymes. European Journal of Pharmacology, 1990, 183, 181.	1.7	0
278	Trichloroethylene Risk Assessment: Relevance of Interindividual Differences. Human and Ecological Risk Assessment (HERA), 2001, 7, 717-726.	1.7	0
279	Modeling and molecular dynamics of glutamine transaminase K/cysteine conjugate Î²-lyase. Journal of Molecular Graphics and Modelling, 2003, 22, 55-70.	1.3	0
280	Effect of polymorphism of CYP2C8 on hydroxylation of diclofenac acyl-glucuronide. Toxicology Letters, 2017, 280, S242.	0.4	0
281	Critique of the â€œCommentâ€•etitled â€œPyrethroid exposure: Not so harmless after allâ€•by Demeneix et al. (2020) published in the lancet diabetes endocrinology. Toxicology Letters, 2021, 340, 1-3.	0.4	0